uniQure Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

uniQure hat ein Gesamteigenkapital von $97.1M und eine Gesamtverschuldung von $518.4M, was einen Verschuldungsgrad von 533.9% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $730.8M bzw. $633.7M.

Wichtige Informationen

533.9%

Verhältnis von Schulden zu Eigenkapital

US$518.45m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$524.43m
Eigenkapital	US$97.11m
Gesamtverbindlichkeiten	US$633.74m
Gesamtvermögen	US$730.85m

Jüngste Berichte zur Finanzlage

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Dec 15

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Aug 27

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Aug 06

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Aug 02

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23

uniQure: Betting On Hemophilia-B Cure

Jan 18

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: QUREDie kurzfristigen Aktiva des Unternehmens ($592.0M) übersteigen seine kurzfristigen Passiva ($80.5M).

Langfristige Verbindlichkeiten: QUREDie kurzfristigen Vermögenswerte des Unternehmens ($592.0M) übersteigen seine langfristigen Verbindlichkeiten ($553.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: QURE über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: QUREDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 27.1% auf 533.9% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: QURE auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: QURE über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 5.2% pro Jahr zurückgeht

uniQure Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Is uniQure (NASDAQ:QURE) A Risky Investment?

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

Consensus revenue estimates decrease by 14%, EPS upgraded

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

New minor risk - Shareholder dilution

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Uniqure N.V. Announces Executive Changes

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 15%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold US$177k worth of stock

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates decrease by 33%, EPS upgraded

New minor risk - Share price stability

uniQure: The Valuation Got More Attractive

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Consensus revenue estimates fall by 35%

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 55%

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Operating Officer notifies of intention to sell stock

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. Announces Executive Changes

New minor risk - Share price stability

Consensus revenue estimates increase by 12%

Consensus revenue estimates fall by 36%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

CEO & Executive Director notifies of intention to sell stock

Consensus EPS estimates fall by 16%

CEO & Executive Director recently sold US$493k worth of stock

CEO & Executive Director notifies of intention to sell stock

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Independent Non-Executive Director exercised options and sold US$103k worth of stock

Independent Non-Executive Director exercised options and sold US$143k worth of stock

CEO & Executive Director recently sold US$149k worth of stock

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Independent Non-Executive Director notifies of intention to sell stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Consensus revenue estimates fall by 51%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Insider exercised options and sold US$123k worth of stock

Investor sentiment improved over the past week